PIK3CA mutations and copy number gains in human lung cancers. - Wikidata - awgldk - TriplyDB

PIK3CA mutations and copy number gains in human lung cancers.

PIK3CA mutations and copy number gains in human lung cancers.

http://www.wikidata.org/entity/Q33870342

about

Should individual PI3 kinase isoforms be targeted in cancer?Molecular biology of lung cancer Molecular biology of lung cancer: clinical implications Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization Nuclear receptor coregulators: modulators of pathology and therapeutic targets Targeting angiogenesis in squamous non-small cell lung cancer Genetic characteristics and research progress of targeted therapy in squamous cell carcinoma Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Oncogenic mutations of PIK3CA in human cancers Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development EGFR-TKI resistance in NSCLC patients: mechanisms and strategies DNA copy number gains in malignant pleural mesothelioma Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets Characteristics of lung cancers harboring NRAS mutations Personalized pathway enrichment map of putative cancer genes from next generation sequencing data A novel classification of lung cancer into molecular subtypes Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study.Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma Molecular pathways and therapeutic targets in lung cancer Amplification of chromosomal segment 4q12 in non-small cell lung cancer ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.Genomics of squamous cell lung cancer PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer.Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer.Lung cancer cell lines as tools for biomedical discovery and research Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.RAS Interaction with PI3K: More Than Just Another Effector Pathway Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.Current concepts on the molecular pathology of non-small cell lung carcinoma.Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

P2860

Q24309044-510D3D88-BA13-4531-81D3-5B7AC8DCE41F Q24606677-CC2F48A6-A7EB-474B-85F4-DAC07252D218 Q24610335-F33B20F2-2397-4BD3-9552-F6FA3137E5EA Q24658420-59AAC330-2062-45B4-B923-823303730542 Q26765060-28E861C0-1D2E-420E-B51E-8F4A6F074B60 Q26859163-4DA85BBF-A679-4FC4-93B7-D520CBA41EC0 Q26861341-1DD79F24-5335-496A-A185-B7B22EAACD87 Q26865529-837D7197-A33C-432D-957F-459244CC9907 Q28086993-A24EA92C-A331-4ACB-A281-92459E90DA04 Q28284802-0FC818D4-81F1-4FAC-90F4-B81F502EAE28 Q28384678-9E530C2F-E318-4CD8-8126-CA038ED4A83C Q28394310-142970A5-D7FB-4D2B-A14B-6E4FCE545631 Q28395184-0BC6E858-E936-4AEC-A03F-1BC288C50B6A Q28480805-E70A3461-92AF-4604-9979-2317A9A996CF Q28550038-45F9FEC4-E523-4485-B973-8F7CACA4A89D Q28608346-8F311313-F825-4028-9E89-2BA2FA48CE0C Q28706226-5DFC08E0-2256-4B4A-80E4-E8C92B70DEE7 Q28729875-B9595524-63BD-4D64-AD0F-C2127E9D18FE Q28731874-649366DD-C80F-49FA-80E1-E6F4326EC73E Q31096247-16A6B722-B427-4A04-A8E4-8F9F69827027 Q33411775-DFC9ED52-70EA-40CC-9820-A76670C901D3 Q33509281-882F3BAB-258D-490A-B204-883837C3452C Q33510334-5C4CE108-8B06-443D-98D6-8293E40B6246 Q33572680-5DC5BCB2-6CC6-4DFE-B324-1B0C4243D58F Q33688872-D3BD8118-4D1E-4E1B-AC4A-D61543BAD924 Q33708516-23241376-B145-46FF-B2EF-576D662C407C Q33719411-3AEBCB1E-F2B7-4052-9E85-6818FC41EA23 Q33752376-7686DD75-A292-4A72-BB70-4FC883917875 Q33763006-28622E14-40EC-436A-B2D1-67AEF4821603 Q33777454-04FCFC70-9633-422E-BB88-1BF1B675291D Q33987852-4821760F-4854-4804-9089-395F72DF8128 Q33988144-86F839E1-D8FF-48F6-94AE-137EB3D804F2 Q33988646-8669BF12-1833-4E30-B099-63A81293863C Q34110617-248441BF-5E81-4F75-91EA-E2FD68502C9B Q34170007-CFEF0775-68F5-4DE0-9BA9-ABC622997F72 Q34202692-9691EBB3-1A3C-4675-85F7-82AB12093558 Q34281228-02295506-B820-4E68-B2C9-DFAEF092E404 Q34310062-574A7FDA-2D63-4DE2-BC80-0CBD64EE5C34 Q34460043-247E0C2C-F498-4EC4-9490-704A89E637F5 Q34460151-87307767-9020-4B3C-9EAF-2B62C031DC90

P2860

PIK3CA mutations and copy number gains in human lung cancers.

http://www.wikidata.org/entity/Q33870342

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

PIK3CA mutations and copy number gains in human lung cancers.

@ast

PIK3CA mutations and copy number gains in human lung cancers.

@en

type

label

PIK3CA mutations and copy number gains in human lung cancers.

@ast

PIK3CA mutations and copy number gains in human lung cancers.

@en

prefLabel

PIK3CA mutations and copy number gains in human lung cancers.

@ast

PIK3CA mutations and copy number gains in human lung cancers.

@en

P1433

Q33870342-23918D63-C8B1-4D07-B37D-F24FB863E3ED

P1476

Q33870342-CEAB474A-A41F-4FAA-BD2F-30487D62ECCB

P2093

Q33870342-2D34695D-702E-4B91-BE4A-4DACA5536F90

Q33870342-2F086D0E-D595-4582-A881-993576D6695D

Q33870342-4B67EFB0-8BCF-4822-8869-4A703169B682

Q33870342-52776C7D-6662-40C1-BDE0-C409B71E1021

Q33870342-53BD13BC-3B7D-4870-8937-89BEF8A7C902

Q33870342-6197C8C1-3ED8-40FB-8E67-A5FAFCE82BD0

Q33870342-71F8346A-2C9C-4F08-9DDE-9D3B00EB1729

Q33870342-7CCCC801-DDB3-4E21-9AF3-A0AD1E9C1A64

Q33870342-7DE522DB-A089-4438-A8B4-B51A4A11E66B

Q33870342-9EF28668-FD7E-477C-BC70-487F37CC58CC

P2860

Q33870342-13AD595F-B6DF-46E7-B00E-D85B35E7357E

Q33870342-1CE251FF-1E5F-4128-8F1E-F3DFFA769711

Q33870342-2D3D1758-131A-44B5-8CB0-239308942883

Q33870342-3F5CFCE7-4D82-45EE-A9FD-61C9BFA5A875

Q33870342-40C3FA54-7083-4894-BAC8-A1690BA984B1

Q33870342-4F02D512-E260-4415-8FEA-EC504CA106C3

Q33870342-4F64DDC8-2824-4F1E-8B13-1B8FAA191006

Q33870342-543788A1-2F3D-4C25-9B27-3FA62198B688

Q33870342-63DD95B8-6D32-4BD9-80AF-21A12D2B5D37

Q33870342-6AB35DBC-E823-47E0-904B-64240D7AD6EA

P304

Q33870342-CDD529EF-B35B-4F87-81EC-BB1AA07C398D

P31

Q33870342-E25F58CD-12CD-4B05-9981-40732A721750

P356

Q33870342-7ECF0476-882D-4E88-8AA7-C6D8D19C1DBC

P407

Q33870342-E6589F79-A61F-4CDA-904A-7698473AF9E9

P433

Q33870342-21917A14-81D8-44B0-9980-3970FDDFF095

P478

Q33870342-18126269-2432-4952-812B-58BE7529A247

P50

Q33870342-3EA7B6C1-A9F3-4C56-A611-CB8738804BA7

P577

Q33870342-88572342-4EF5-4D3A-9827-13D8EDD14141

P698

Q33870342-96038E38-48C2-4381-966F-AEFF8D79289F

P932

Q33870342-86B723D5-E882-4BBB-BE70-358FF7EBBAFF

P356

0008-5472.CAN-07-5084

P1433

Cancer Research

P1476

PIK3CA mutations and copy number gains in human lung cancers.

@en

P2093

Adi F Gazdar

http://www.w3.org/2001/XMLSchema#string

Hiromasa Yamamoto

http://www.w3.org/2001/XMLSchema#string

Hiroshi Date

http://www.w3.org/2001/XMLSchema#string

Hisayuki Shigematsu

http://www.w3.org/2001/XMLSchema#string

Huei Lee

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

Junichi Soh

http://www.w3.org/2001/XMLSchema#string

Kwun M Fong

http://www.w3.org/2001/XMLSchema#string

Makoto Suzuki

http://www.w3.org/2001/XMLSchema#string

Masaharu Nomura

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation of the PTEN tail regulates protein stability and function

siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

High frequency of mutations of the PIK3CA gene in human cancers

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Cancer genes and the pathways they control

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

P304

6913-6921

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-07-5084

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Ignacio I Wistuba

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18757405

http://www.w3.org/2001/XMLSchema#string

P932

2874836

http://www.w3.org/2001/XMLSchema#string